Status:
COMPLETED
Survey to Assess Physicians' Knowledge of Exjade Posology and Biological Monitoring Recommendations as Described in the Educational Materials
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Chronic Iron Overload
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this survey is to assess the knowledge of HCPs in relation to the recommended posology and biological monitoring for Exjade, based on the current locally valid Exjade educational mate...
Eligibility Criteria
Inclusion
- Physicians will be required to meet all of the following inclusion criteria:
- Must provide consent for participation
- Must spend ≥50% of time in direct patient care
- Have treated patients with transfusional iron overload or non-transfusion-dependent thalassemia with chelation therapy during the last 12 months.
- Have prescribed Exjade and/or generic deferasirox within the last 12 months.
Exclusion
- Physicians meeting the following criterion will not be eligible to take the survey:
- • Currently employed by a pharmaceutical company, health care company, market research company, advertising agency, or government agency involved in pharmaceutical research or marketing.
Key Trial Info
Start Date :
January 12 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 15 2024
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06215287
Start Date
January 12 2024
End Date
February 15 2024
Last Update
May 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Basel, Switzerland